TransMedics Group (NASDAQ:TMDX) Hits New 52-Week Low - Time to Sell?

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report)'s share price reached a new 52-week low during trading on Thursday . The stock traded as low as $60.40 and last traded at $60.88, with a volume of 1588704 shares traded. The stock had previously closed at $65.71.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on TMDX. JPMorgan Chase & Co. reaffirmed a "neutral" rating and set a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday. Robert W. Baird dropped their price target on shares of TransMedics Group from $150.00 to $120.00 and set an "outperform" rating on the stock in a research report on Wednesday, December 11th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Wednesday, December 11th. Baird R W raised shares of TransMedics Group to a "strong-buy" rating in a research note on Tuesday, September 24th. Finally, Canaccord Genuity Group cut their price target on TransMedics Group from $109.00 to $104.00 and set a "buy" rating for the company in a research note on Wednesday, November 20th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, TransMedics Group currently has a consensus rating of "Moderate Buy" and a consensus price target of $122.70.

TransMedics Group Trading Down 0.6 %

The company has a fifty day moving average of $89.89 and a 200-day moving average of $129.32. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The company has a market capitalization of $2.03 billion, a price-to-earnings ratio of 64.39 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.29 by ($0.17). The business had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm's revenue was up 63.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.12) EPS. As a group, equities research analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Edward M. Basile sold 6,750 shares of the firm's stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the completion of the sale, the director now owns 732 shares in the company, valued at $61,158.60. This trade represents a 90.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of the company's stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the transaction, the insider now owns 20,843 shares in the company, valued at $3,089,766.32. This represents a 12.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 19,417 shares of company stock valued at $2,240,738. Insiders own 7.00% of the company's stock.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TMDX. Driehaus Capital Management LLC lifted its holdings in shares of TransMedics Group by 15.8% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company's stock worth $223,832,000 after acquiring an additional 202,867 shares during the last quarter. Principal Financial Group Inc. raised its position in TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company's stock valued at $31,759,000 after purchasing an additional 146,115 shares during the period. Hood River Capital Management LLC acquired a new position in TransMedics Group during the second quarter worth $18,854,000. Canada Pension Plan Investment Board purchased a new position in shares of TransMedics Group during the second quarter worth $16,086,000. Finally, F M Investments LLC acquired a new stake in shares of TransMedics Group in the second quarter valued at $10,957,000. Institutional investors and hedge funds own 99.67% of the company's stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.